Logo image of QLGN

QUALIGEN THERAPEUTICS INC (QLGN) Stock Fundamental Analysis

NASDAQ:QLGN - Nasdaq - US74754R3012 - Common Stock - Currency: USD

1.82  -0.03 (-1.62%)

After market: 1.82 0 (0%)

Fundamental Rating

2

QLGN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 551 industry peers in the Biotechnology industry. QLGN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. QLGN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

QLGN had negative earnings in the past year.
In the past year QLGN has reported a negative cash flow from operations.
In the past 5 years QLGN always reported negative net income.
QLGN had a negative operating cash flow in each of the past 5 years.
QLGN Yearly Net Income VS EBIT VS OCF VS FCFQLGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

With a Return On Assets value of -242.33%, QLGN is not doing good in the industry: 91.29% of the companies in the same industry are doing better.
QLGN has a Return On Equity of -20846.83%. This is amonst the worse of the industry: QLGN underperforms 84.39% of its industry peers.
Industry RankSector Rank
ROA -242.33%
ROE -20846.83%
ROIC N/A
ROA(3y)-278.66%
ROA(5y)-298%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
QLGN Yearly ROA, ROE, ROICQLGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

QLGN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QLGN Yearly Profit, Operating, Gross MarginsQLGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for QLGN has been increased compared to 1 year ago.
The number of shares outstanding for QLGN has been increased compared to 5 years ago.
There is no outstanding debt for QLGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
QLGN Yearly Shares OutstandingQLGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
QLGN Yearly Total Debt VS Total AssetsQLGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

QLGN has an Altman-Z score of -68.69. This is a bad value and indicates that QLGN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -68.69, QLGN is doing worse than 95.10% of the companies in the same industry.
QLGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -68.69
ROIC/WACCN/A
WACCN/A
QLGN Yearly LT Debt VS Equity VS FCFQLGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 1.01 indicates that QLGN should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.01, QLGN is doing worse than 88.20% of the companies in the same industry.
QLGN has a Quick Ratio of 1.01. This is a normal value and indicates that QLGN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.01, QLGN is doing worse than 87.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 1.01
QLGN Yearly Current Assets VS Current LiabilitesQLGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

QLGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.69%, which is quite impressive.
The Revenue for QLGN has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)57.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.68%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

QLGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.80% yearly.
The Revenue is expected to decrease by -41.42% on average over the next years. This is quite bad
EPS Next Y62.96%
EPS Next 2Y31.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

QLGN Yearly Revenue VS EstimatesQLGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 1M 2M 3M 4M 5M
QLGN Yearly EPS VS EstimatesQLGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2021 2022 2023 2024 2025 -50K -100K -150K -200K -250K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for QLGN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QLGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QLGN Price Earnings VS Forward Price EarningsQLGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QLGN Per share dataQLGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as QLGN's earnings are expected to grow with 31.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.8%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

QLGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

QUALIGEN THERAPEUTICS INC

NASDAQ:QLGN (8/8/2025, 8:02:11 PM)

After market: 1.82 0 (0%)

1.82

-0.03 (-1.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-21 2025-07-21
Earnings (Next)08-12 2025-08-12
Inst Owners1.17%
Inst Owner Change-83.67%
Ins Owners0.09%
Ins Owner Change0%
Market Cap2.98M
Analysts82.86
Price TargetN/A
Short Float %1.56%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 90.18
P/tB 90.18
EV/EBITDA N/A
EPS(TTM)-17.96
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-4.35
FCFYN/A
OCF(TTM)-4.35
OCFYN/A
SpS0
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -242.33%
ROE -20846.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-278.66%
ROA(5y)-298%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.01
Quick Ratio 1.01
Altman-Z -68.69
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.68%
EPS Next Y62.96%
EPS Next 2Y31.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y57.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.85%
OCF growth 3YN/A
OCF growth 5YN/A